Clinical and in vitro evidence for the antimicrobial therapy in Burkholderia cepacia complex infections

References:

• Tablan OC, Chorba TL, Schidlow DV, et al. Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J Pediatr 1985;107(3):382-7
   PubMed Web of Science ®Google Scholar
• Sousa SA, Ramos CG, Leitao JH. Burkholderia cepacia Complex: Emerging Multihost Pathogens Equipped with a Wide Range of Virulence Factors and Determinants. Int J Microbiol 2011;2011; Article ID 607575
   PubMedGoogle Scholar
• Vanlaere E, Lipuma JJ, Baldwin A, et al. Burkholderia latens sp. nov., Burkholderia diffusa sp. nov., Burkholderia arboris sp. nov., Burkholderia seminalis sp. nov. and Burkholderia metallica sp. nov., novel species within the Burkholderia cepacia complex. Int J Syst Evol Microbiol 2008;58(Pt 7):1580-90
   PubMedGoogle Scholar
• LiPuma JJ, Currie BJ, Lum GD, Vandamme PAR. Burkholderia, Stenotrophomonas, Ralstonia, Cupriavidus, Pandoraea, Brevundimonas, Comamonas and Acidovorax. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, Editors Manual of clinical Microbiology. ASM Press, Washington, DC, 2007;749-69
   Google Scholar
• Peeters C, Zlosnik JE, Spilker T, et al. Burkholderia pseudomultivorans sp. nov., a novel Burkholderia cepacia complex species from human respiratory samples and the rhizosphere. Syst Appl Microbiol 2013;36(7):483-9
   PubMed Web of Science ®Google Scholar
• Burkholder W. Sour skin, a bacterial rot of onion bulbs. Phytopathology 1950;40:115-18
   Web of Science ®Google Scholar
• Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002;15(2):194-222
   PubMed Web of Science ®Google Scholar
• Robinson M, Bye PT. Mucociliary clearance in cystic fibrosis. Pediatr Pulmonol 2002;33(4):293-306
   PubMed Web of Science ®Google Scholar
• Flume PA, Mogayzel PJJr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180(9):802-8
   PubMed Web of Science ®Google Scholar
• Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax 2007;62(4):360-7
   PubMed Web of Science ®Google Scholar
• Govan JR, Brown AR, Jones AM. Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection. Future Microbiol 2007;2(2):153-64
   PubMed Web of Science ®Google Scholar
• Zahariadis G, Levy MH, Burns JL. Cepacia-like syndrome caused by Burkholderia multivorans. Can J Infect Dis 2003;14(2):123-5
   PubMedGoogle Scholar
• Kalish LA, Waltz DA, Dovey M, et al. Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am J Respir Crit Care Med 2006;173(4):421-5
   PubMedGoogle Scholar
• Sass A, Marchbank A, Tullis E, et al. Spontaneous and evolutionary changes in the antibiotic resistance of Burkholderia cenocepacia observed by global gene expression analysis. BMC Genomics 2011;12:373
   PubMedGoogle Scholar
• Hughes JE, Stewart J, Barclay GR, Govan JR. Priming of neutrophil respiratory burst activity by lipopolysaccharide from Burkholderia cepacia. Infect Immun 1997;65(10):4281-7
   PubMed Web of Science ®Google Scholar
• Davies J, Neth O, Alton E, et al. Differential binding of mannose-binding lectin to respiratory pathogens in cystic fibrosis. Lancet 2000;355(9218):1885-6
   PubMedGoogle Scholar
• Cazzola G, Amalfitano G, Tonolli E, et al. Burkholderia (Pseudomonas) cepacia epidemiology in a cystic fibrosis population: a genome finger-printing study. Acta Paediatr 1996;85(5):554-7
   PubMedGoogle Scholar
• Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010;23(2):299-323
   PubMed Web of Science ®Google Scholar
• Zlosnik JE, Zhou G, Brant R, et al. Burkholderia species infections in patients with cystic fibrosis in british columbia, Canada. 30 years’ experience. Ann Am Thorac Soc 2015;12(1):70-8
   PubMedGoogle Scholar
• Brisse S, Cordevant C, Vandamme P, et al. Species distribution and ribotype diversity of Burkholderia cepacia complex isolates from French patients with cystic fibrosis. J Clin Microbiol 2004;42(10):4824-7
   PubMedGoogle Scholar
• Drevinek P, Cinek O, Melter J, et al. Genomovar distribution of the Burkholderia cepacia complex differs significantly between Czech and Slovak patients with cystic fibrosis. J Med Microbiol 2003;52(Pt 7):603-4
   PubMedGoogle Scholar
• Kidd TJ, Douglas JM, Bergh HA, et al. Burkholderia cepacia complex epidemiology in persons with cystic fibrosis from Australia and New Zealand. Res Microbiol 2008;159(3):194-9
   PubMed Web of Science ®Google Scholar
• McDowell A, Mahenthiralingam E, Dunbar KE, et al. Epidemiology of Burkholderia cepacia complex species recovered from cystic fibrosis patients: issues related to patient segregation. J Med Microbiol 2004;53(Pt 7):663-8
   PubMedGoogle Scholar
• Golini G, Cazzola G, Fontana R. Molecular epidemiology and antibiotic susceptibility of Burkholderia cepacia-complex isolates from an Italian cystic fibrosis centre. Eur J Clin Microbiol Infect Dis 2006;25(3):175-80
   PubMedGoogle Scholar
• Gautam V, Ray P, Puri GD, et al. Investigation of Burkholderia cepacia complex in septicaemic patients in a tertiary care hospital. India. Nepal Med Coll J 2009;11(4):222-4
   PubMedGoogle Scholar
• Coutinho CP, Dos Santos SC, Madeira A, et al. Long-Term Colonization of the Cystic Fibrosis Lung by Burkholderia cepacia Complex Bacteria: epidemiology, Clonal Variation, and Genome-Wide Expression Alterations. Front Cell Infect Microbiol 2011;1:12
   PubMedGoogle Scholar
• Biddick R, Spilker T, Martin A, LiPuma JJ. Evidence of transmission of Burkholderia cepacia, Burkholderia multivorans and Burkholderia dolosa among persons with cystic fibrosis. FEMS Microbiol Lett 2003;228(1):57-62
   PubMedGoogle Scholar
• Reik R, Spilker T, Lipuma JJ. Distribution of Burkholderia cepacia complex species among isolates recovered from persons with or without cystic fibrosis. J Clin Microbiol 2005;43(6):2926-8
   PubMedGoogle Scholar
• Drevinek P, Mahenthiralingam E. Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence. Clin Microbiol Infect 2010;16(7):821-30
   PubMed Web of Science ®Google Scholar
• Baldwin A, Mahenthiralingam E, Drevinek P, et al. Environmental Burkholderia cepacia complex isolates in human infections. Emerg Infect Dis 2007;13(3):458-61
   PubMed Web of Science ®Google Scholar
• Barrado L, Martinez MT, Villa J, et al. Clonal diversity among Burkholderia cepacia complex isolates from cystic fibrosis patients in a reference unit. Enferm Infecc Microbiol Clin 2013;31(10):665-8
   PubMedGoogle Scholar
• Crowley D, Daly M, Lucey B, et al. Molecular epidemiology of cystic fibrosis-linked Burkholderia cepacia complex isolates from three national referral centres in Ireland. J Appl Microbiol 2002;92(5):992-1004
   PubMedGoogle Scholar
• Voronina AL, Chernukha MY, Shaginyan IA, et al. [Characterization of genotypes for Burkholderia cepacia complex strains isolated from patients in hospitals of Russian Federation]. Mol Gen Mikrobiol Virusol 2013(2):22-30
   Google Scholar
• Lynch JP3rd. Burkholderia cepacia complex: impact on the cystic fibrosis lung lesion. Semin Respir Crit Care Med 2009;30(5):596-610
   PubMed Web of Science ®Google Scholar
• Jones AM, Dodd ME, Govan JR, et al. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax 2004;59(11):948-51
   PubMed Web of Science ®Google Scholar
• Gautam V, Singh M, Singhal L, et al. Burkholderia cepacia complex in Indian cystic fibrosis patients. Indian J Med Res 2012;136(5):882-3
   PubMedGoogle Scholar
• Saiman L, Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am J Infect Control 2003;31(3 Suppl):S1-62
   PubMed Web of Science ®Google Scholar
• Duff AJ. Psychological consequences of segregation resulting from chronic Burkholderia cepacia infection in adults with CF. Thorax 2002;57(9):756-8
   PubMedGoogle Scholar
• Bonacorsi S, Fitoussi F, Lhopital S, Bingen E. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1999;43(2):213-17
   PubMed Web of Science ®Google Scholar
• Zhou J, Chen Y, Tabibi S, et al. Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2007;51(3):1085-8
   PubMedGoogle Scholar
• Avgeri SG, Matthaiou DK, Dimopoulos G, et al. Therapeutic options for Burkholderia cepacia infections beyond co-trimoxazole: a systematic review of the clinical evidence. Int J Antimicrob Agents 2009;33(5):394-404
   PubMed Web of Science ®Google Scholar
• George AM, Jones PM, Middleton PG. Cystic fibrosis infections: treatment strategies and prospects. FEMS Microbiol Lett 2009;300(2):153-64
   PubMed Web of Science ®Google Scholar
• Horsley A, Jones AM. Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation. Cochrane Database Syst Rev 2012;10:CD009529
   PubMedGoogle Scholar
• Southern KW, Barker PM, Solis-Moya A, Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2012;11;CD002203
   Google Scholar
• Mc Manus TE, Moore JE, Crowe M, et al. A comparison of pulmonary exacerbations with single and multiple organisms in patients with cystic fibrosis and chronic Burkholderia cepacia infection. J Infect 2003;46(1):56-9
   PubMedGoogle Scholar
• Blackburn L, Brownlee K, Conway S, Denton M. ’Cepacia syndrome’ with Burkholderia multivorans, 9 years after initial colonization. J Cyst Fibros 2004;3(2):133-4
   PubMedGoogle Scholar
• Lekkas A, Gyi KM, Hodson ME. Temocillin in the treatment of Burkholderia cepacia infection in cystic fibrosis. J Cyst Fibros 2006;5(2):121-4
   PubMed Web of Science ®Google Scholar
• Moriarty TF, McElnay JC, Elborn JS, Tunney MM. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection. Pediatr Pulmonol 2007;42(11):1008-17
   PubMedGoogle Scholar
• Weidmann A, Webb AK, Dodd ME, Jones AM. Successful treatment of cepacia syndrome with combination nebulised and intravenous antibiotic therapy. J Cyst Fibros 2008;7(5):409-11
   PubMedGoogle Scholar
• Nash EF, Thomas A. Whitmill R, et al. "Cepacia syndrome" associated with Burkholderia cepacia (genomovar I) infection in an adolescent with cystic fibrosis. Pediatr Pulmonol 2010;46(5):512-14
   PubMedGoogle Scholar
• Castro-Elias WA, Singh S, Hiatt PW, et al. Efficacy of ivacaftor in a child with cystic fibrosis, end-stage lung disease, and cepacia syndrome. Pediat Allergy Immunol Pulmonol 2012;4(25):231-3
   Google Scholar
• El-Laboudi AH, Etherington C, Whitaker P, et al. Acute Burkholderia cenocepacia pyomyositis in a patient with cystic fibrosis. J Cyst Fibros 2009;8(4):273-5
   PubMedGoogle Scholar
• George RB, Cartier Y, Casson AG, Hernandez P. Suppurative mediastinitis secondary to Burkholderia cepacia in a patient with cystic fibrosis. Can Respir J 2006;13(4):215-18
   PubMedGoogle Scholar
• Kazachkov M, Lager J, LiPuma J, Barker PM. Survival following Burkholderia cepacia sepsis in a patient with cystic fibrosis treated with corticosteroids. Pediatr Pulmonol 2001;32(4):338-40
   PubMedGoogle Scholar
• Etherington C, Peckham DG, Conway SP, Denton M. Burkholderia cepacia complex infection in adult patients with cystic fibrosis – is early eradication possible? J Cyst Fibros 2003;2(4):220-1
   PubMedGoogle Scholar
• Stokell JR, Gharaibeh RZ, Steck TR. Rapid emergence of a ceftazidime-resistant Burkholderia multivorans strain in a Cystic Fibrosis patient. J Cyst Fibros 2013;12(6):812-16
   PubMedGoogle Scholar
• Horsley A, Webb K, Bright-Thomas R, et al. Can early Burkholderia cepacia Complex Infection in Cystic Fibrosis be Eradicated with Antibiotic Therapy? Front Cell Infect Microbiol 2011;1:18
   PubMed Web of Science ®Google Scholar
• Blumer JL, Saiman L, Konstan MW, Melnick D. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 2005;128(4):2336-46
   PubMedGoogle Scholar
• Taccetti G, Campana S, Marianelli L. Multiresistant non-fermentative gram-negative bacteria in cystic fibrosis patients: the results of an Italian multicenter study. Italian Group for Cystic Fibrosis microbiology. Eur J Epidemiol 1999;15(1):85-8
   PubMed Web of Science ®Google Scholar
• Kurlandsky LE, Fader RC. In vitro activity of minocycline against respiratory pathogens from patients with cystic fibrosis. Pediatr Pulmonol 2000;29(3):210-12
   PubMedGoogle Scholar
• Moore JE, Crowe M, Shaw A, et al. Antibiotic resistance in Burkholderia cepacia at two regional cystic fibrosis centres in Northern Ireland: is there a need for synergy testing? J Antimicrob Chemother 2001;48(2):319-21
   PubMedGoogle Scholar
• MacKenzie FM, Smith SV, Milne KE, et al. Antibiograms of resistant Gram-negative bacteria from Scottish CF patients. J Cyst Fibros 2004;3(3):151-7
   PubMedGoogle Scholar
• Traczewski MM, Brown SD. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob Agents Chemother 2006;50(2):819-21
   PubMedGoogle Scholar
• Al-Bakri AG, Gilbert P, Allison DG. Influence of gentamicin and tobramycin on binary biofilm formation by co-cultures of Burkholderia cepacia and Pseudomonas aeruginosa. J Basic Microbiol 2005;45(5):392-6
   PubMedGoogle Scholar
• Leitao JH, Sousa SA, Cunha MV, et al. Variation of the antimicrobial susceptibility profiles of Burkholderia cepacia complex clonal isolates obtained from chronically infected cystic fibrosis patients: a five-year survey in the major Portuguese treatment center. Eur J Clin Microbiol Infect Dis 2008;27(11):1101-11
   PubMedGoogle Scholar
• Peeters E, Nelis HJ, Coenye T. In vitro activity of ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin and trimethoprim/sulfamethoxazole against planktonic and sessile Burkholderia cepacia complex bacteria. J Antimicrob Chemother 2009;64(4):801-9
   PubMed Web of Science ®Google Scholar
• LiPuma JJ, Rathinavelu S, Foster BK, et al. In vitro activities of a novel nanoemulsion against Burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species. Antimicrob Agents Chemother 2009;53(1):249-55
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Ge Y, Warner M. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Int J Antimicrob Agents 2009;34(5):402-6
   PubMed Web of Science ®Google Scholar
• Thwaite JE, Humphrey S, Fox MA, et al. The cationic peptide magainin II is antimicrobial for Burkholderia cepacia-complex strains. J Med Microbiol 2009;58(Pt 7):923-9
   PubMedGoogle Scholar
• King P, Lomovskaya O, Griffith DC, et al. In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. Antimicrob Agents Chemother 2010;54(1):143-8
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Warner M, Livermore D. Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters. J Antimicrob Chemother 2010;65(2):266-70
   PubMed Web of Science ®Google Scholar
• Major TA, Panmanee W, Mortensen JE, et al. Sodium nitrite-mediated killing of the major cystic fibrosis pathogens Pseudomonas aeruginosa, Staphylococcus aureus, and Burkholderia cepacia under anaerobic planktonic and biofilm conditions. Antimicrob Agents Chemother 2010;54(11):4671-7
   PubMed Web of Science ®Google Scholar
• Messiaen AS, Verbrugghen T, Declerck C, et al. Resistance of the Burkholderia cepacia complex to fosmidomycin and fosmidomycin derivatives. Int J Antimicrob Agents 2011;38(3):261-4
   PubMedGoogle Scholar
• Livermore DM, Mushtaq S, Warner M, Woodford N. Comparative in vitro activity of sulfametrole/trimethoprim and sulfamethoxazole/trimethoprim and other agents against multiresistant Gram-negative bacteria. J Antimicrob Chemother 2014;69(4):1050-6
   PubMed Web of Science ®Google Scholar
• Correa-Ruiz A, Giron R, Buendia B, et al. Burkholderia cepacia complex infection in an Adult Cystic Fibrosis unit in Madrid. Enferm Infecc Microbiol Clin 2013;31(10):649-54
   PubMedGoogle Scholar
• Saiman L, Chen Y, Gabriel PS, Knirsch C. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2002;46(4):1105-7
   PubMed Web of Science ®Google Scholar
• Aaron SD, Ferris W, Henry DA, et al. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 2000;161(4 Pt 1):1206-12
   PubMed Web of Science ®Google Scholar
• MacLeod DL, Barker LM, Sutherland JL, et al. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother 2009;64(4):829-36
   PubMed Web of Science ®Google Scholar
• Dales L, Ferris W, Vandemheen K, Aaron SD. Combination antibiotic susceptibility of biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosis. Eur J Clin Microbiol Infect Dis 2009;28(10):1275-9
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Warner M, Livermore DM. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. J Antimicrob Chemother 2010;65(11):2376-81
   PubMed Web of Science ®Google Scholar
• Van Acker H, Van Snick E, Nelis HJ, Coenye T. In vitro activity of temocillin against planktonic and sessile Burkholderia cepacia complex bacteria. J Cyst Fibros 2010;9(6):450-4
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M. Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms. J Antimicrob Chemother 2010;65(11):2382-95
   PubMedGoogle Scholar
• McGhee P, Clark C, Credito K, et al. In vitro activity of fusidic acid (CEM-102, sodium fusidate) against Staphylococcus aureus isolates from cystic fibrosis patients and its effect on the activities of tobramycin and amikacin against Pseudomonas aeruginosa and Burkholderia cepacia. Antimicrob Agents Chemother 2011;55(5):2417-19
   PubMedGoogle Scholar
• Tunney MM, Scott EM. Use of breakpoint combination sensitivity testing as a simple and convenient method to evaluate the combined effects of ceftazidime and tobramycin on Pseudomonas aeruginosa and Burkholderia cepacia complex isolates in vitro. J Microbiol Methods 2004;57(1):107-14
   PubMedGoogle Scholar
• Manno G, Ugolotti E, Belli ML, et al. Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2003;22(1):28-34
   PubMedGoogle Scholar
• Conway SP, Brownlee KG, Denton M, Peckham DG. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis. Am J Respir Med 2003;2(4):321-32
   PubMedGoogle Scholar
• Aaron SD. Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms. Paediatr Respir Rev 2007;8(3):256-61
   PubMedGoogle Scholar
• Simon A, Bode U, Beutel K. Diagnosis and treatment of catheter-related infections in paediatric oncology: an update. Clin Microbiol Infect 2006;12(7):606-20
   PubMed Web of Science ®Google Scholar
• Aggarwal N, Garg S, Pannu HS, Kler TS. Fatal Burkholderia cepacia early prosthetic valve endocarditis: a very rare case and a review of the literature. J Heart Valve Dis 2005;14(2):271-4
   PubMedGoogle Scholar
• Blumer JL, Stern RC, Klinger JD, et al. Ceftazidime therapy in patients with cystic fibrosis and multiply-drug-resistant pseudomonas. Am J Med 1985;79(2A):37-46
   PubMedGoogle Scholar
• Isles A, Maclusky I, Corey M, et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 1984;104(2):206-10
   PubMed Web of Science ®Google Scholar
• Martone WJ, Osterman CA, Fisher KA, Wenzel RP. Pseudomonas cepacia: implications and control of epidemic nosocomial colonization. Rev Infect Dis 1981;3(4):708-15
   PubMedGoogle Scholar
• Moore RA, Hancock RE. Involvement of outer membrane of Pseudomonas cepacia in aminoglycoside and polymyxin resistance. Antimicrob Agents Chemother 1986;30(6):923-6
   PubMedGoogle Scholar
• Magalhaes M, de Britto MC, Vandamme P. Burkholderia cepacia genomovar III and Burkholderia vietnamiensis double infection in a cystic fibrosis child. J Cyst Fibros 2002;1(4):292-4
   PubMedGoogle Scholar
• Lekstrom-Himes JA, Gallin JI. Immunodeficiency diseases caused by defects in phagocytes. N Engl J Med 2000;343(23):1703-14
   PubMed Web of Science ®Google Scholar
• Margolis DM, Melnick DA, Alling DW, Gallin JI. Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis 1990;162(3):723-6
   PubMed Web of Science ®Google Scholar
• McGowan JEJr. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Infect Control 2006;34(5 Suppl 1):S29-37; discussion S64-73
   PubMedGoogle Scholar
• Pitt TL, Kaufmann ME, Patel PS, et al. Type characterisation and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland. J Med Microbiol 1996;44(3):203-10
   PubMed Web of Science ®Google Scholar
• Yildiz B, Duyu M, Sozeri B, Karapinar B. Soft tissue infection caused by burkholderia cepacia in a child with polyarteritis nodosa. Turk J Pediatr 2012;54(6):664-6
   PubMedGoogle Scholar
• Lu DC, Chang SC, Chen YC, et al. In vitro activities of antimicrobial agents, alone and in combinations, against Burkholderia cepacia isolated from blood. Diagn Microbiol Infect Dis 1997;28(4):187-91
   PubMedGoogle Scholar
• Lu DC, Chang SC, Chen YC, et al. Burkholderia cepacia bacteremia: a retrospective analysis of 70 episodes. J Formos Med Assoc 1997;96(12):972-8
   PubMed Web of Science ®Google Scholar
• Durham SH, Lee AE, Assanasen C. Burkholderia cepacia septicemia in a pediatric oncology patient: a pharmacotherapy challenge. Ann Pharmacother 2012;46(6):e16
   Google Scholar
• Prince A, Wood MS, Cacalano GS, Chin NX. Isolation and characterization of a penicillinase from Pseudomonas cepacia 249. Antimicrob Agents Chemother 1988;32(6):838-43
   PubMedGoogle Scholar
• Simpson IN, Finlay J, Winstanley DJ, et al. Multi-resistance isolates possessing characteristics of both Burkholderia (Pseudomonas) cepacia and Burkholderia gladioli from patients with cystic fibrosis. J Antimicrob Chemother 1994;34(3):353-61
   PubMedGoogle Scholar
• Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2014;1:CD003344
   PubMed Web of Science ®Google Scholar
• Traugott KA, Echevarria K, Maxwell P, et al. Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum. Pharmacotherapy 2011;31(6):598-608
   PubMedGoogle Scholar
• Hu Y, Li L, Li W, et al. Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies. Int J Antimicrob Agents 2013;42(6):492-6
   PubMed Web of Science ®Google Scholar
• Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet 1985;1(8433):865
   PubMed Web of Science ®Google Scholar
• Smyth AR, Bell SC, Bojcin S, et al. European Cystic Fibrosis Society Standards of Care: best Practice guidelines. J Cyst Fibros 2014;13(Suppl 1):S23-42
   PubMed Web of Science ®Google Scholar
• Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991;338(8769):725-6
   PubMed Web of Science ®Google Scholar
• Conway SP, Lee TW. Prevention of chronic Pseudomonas aeruginosa infection in people with cystic fibrosis. Expert Rev Respir Med 2009;3(4):349-61
   PubMedGoogle Scholar
• Lillquist YP, Cho E, Davidson AG. Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009. J Cyst Fibros 2011;10(3):175-80
   PubMedGoogle Scholar
• St Denis M, Ramotar K, Vandemheen K, et al. Infection with Burkholderia cepacia complex bacteria and pulmonary exacerbations of cystic fibrosis. Chest 2007;131(4):1188-96
   PubMedGoogle Scholar
• Gold HS, Pillai SK. Antistaphylococcal agents. Infect Dis Clin North Am 2009;23(1):99-131
   PubMedGoogle Scholar
• Ball R, Brownlee KG, Duff AJ, et al. Can Burkholderia cepacia complex be eradicated with nebulised amiloride and TOBI? J Cyst Fibros 2010;9(1):73-4
   PubMedGoogle Scholar
• Middleton PG, Kidd TJ, Williams B. Combination aerosol therapy to treat Burkholderia cepacia complex. Eur Respir J 2005;26(2):305-8
   PubMed Web of Science ®Google Scholar
• Uluer AZ, Waltz DA, Kalish LA, et al. Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis. J Cyst Fibros 2013;12(1):54-9
   PubMedGoogle Scholar
• Snell GI, de Hoyos A, Krajden M, et al. Pseudomonas cepacia in lung transplant recipients with cystic fibrosis. Chest 1993;103(2):466-71
   PubMed Web of Science ®Google Scholar
• Noyes BE, Michaels MG, Kurland G, et al. Pseudomonas cepacia empyema necessitatis after lung transplantation in two patients with cystic fibrosis. Chest 1994;105(6):1888-91
   PubMedGoogle Scholar
• Ciofu O, Jensen T, Pressler T, et al. Meropenem in cystic fibrosis patients infected with resistant Pseudomonas aeruginosa or Burkholderia cepacia and with hypersensitivity to beta-lactam antibiotics. Clin Microbiol Infect 1996;2(2):91-8
   PubMedGoogle Scholar
• Balfour-Lynn IM, Ryley HC, Whitehead BF. Subdural empyema due to Burkholderia cepacia: an unusual complication after lung transplantation for cystic fibrosis. J R Soc Med 1997;90(Suppl 31):59-64
   PubMedGoogle Scholar
• Ledson MJ, Cowperthwaite C, Walshaw MJ, et al. Nebulised taurolidine and B cepacia bronchiectasis. Thorax 2000;55(1):91-2
   PubMedGoogle Scholar
• Nash EF, Thomas A, Whitmill R, et al. “Cepacia syndrome” associated with Burkholderia cepacia (Genomovar I) infection in an adolescent with cystic fibrosis. Pediatr Pulmonol 2011;46(5):512-14
   PubMedGoogle Scholar
• Zobell JT, Kemper AL, Young DC. The use of doripenem in pediatric cystic fibrosis patients in case of meropenem shortages. Pediatr Pulmonol 2014;49(3):E48-51
   Google Scholar
• Tullis DE, Burns JL, Retsch-Bogart GZ, et al. Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial. J Cyst Fibros 2014;13(3):296-305
   PubMed Web of Science ®Google Scholar
• Antibiotic Consensus Group. Antibiotic treatment for cystic fibrosis – report of the UK Cystic Fibrosis Trust Antibiotic Group. (2002)
   Google Scholar
• Flume PA, O’Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007;176(10):957-69
   PubMed Web of Science ®Google Scholar
• Cystic Fibrosis F, Borowitz D, Parad RB, et al. Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. J Pediatr 2009;155(6 Suppl):S106-16
   PubMed Web of Science ®Google Scholar
• Nash EF, Coonar A, Kremer R, et al. Survival of Burkholderia cepacia sepsis following lung transplantation in recipients with cystic fibrosis. Transpl Infect Dis 2010;12(6):551-4
   PubMed Web of Science ®Google Scholar
• Sawicki GS, Signorovitch JE, Zhang J, et al. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol 2012;47(1):44-52
   PubMed Web of Science ®Google Scholar
• Grimwood K, Kidd TJ, Tweed M. Successful treatment of cepacia syndrome. J Cyst Fibros 2009;8(4):291-3
   PubMedGoogle Scholar
• Amin R, Subbarao P, Lou W, et al. The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis. Eur Respir J 2011;37(4):806-12
   PubMed Web of Science ®Google Scholar
• Cohn RC, Aronoff SC. The effect of sodium on amiloride-tobramycin synergy in Pseudomonas cepacia. J Lab Clin Med 1989;114(6):724-7
   PubMedGoogle Scholar
• Gibson RL, Retsch-Bogart GZ, Oermann C, et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol 2006;41(7):656-65
   PubMed Web of Science ®Google Scholar
• Sawicki GS, Signorovitch JE, Zhang J, et al. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol 2012;47(1):44-52
   PubMed Web of Science ®Google Scholar
• Sabet M, Miller CE, Nolan TG, et al. Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009;53(9):3923-8
   PubMed Web of Science ®Google Scholar
• Geller DE, Flume PA, Griffith DC, et al. Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob Agents Chemother 2011;55(6):2636-40
   PubMed Web of Science ®Google Scholar
• Geller DE, Flume PA, Staab D, et al. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011;183(11):1510-16
   PubMed Web of Science ®Google Scholar
• Stockmann C, Sherwin CM, Ampofo K, Spigarelli MG. Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosis. Ther Adv Respir Dis 2014;8(1):13-21
   PubMedGoogle Scholar
• Okusanya OO, Bhavnani SM, Hammel JP, et al. Evaluation of the pharmacokinetic-pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies. Antimicrob Agents Chemother 2014;58(9):5005-15
   PubMed Web of Science ®Google Scholar
• Rowe SM, Borowitz DS, Burns JL, et al. Progress in cystic fibrosis and the CF Therapeutics Development Network. Thorax 2012;67(10):882-90
   PubMed Web of Science ®Google Scholar
• Stass H, Weimann B, Nagelschmitz J, et al. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. Clin Ther 2013;35(10):1571-81
   PubMed Web of Science ®Google Scholar
• Gautam V, Arora A, Madhup SK, et al. Burkholderia cepacia complex in septicaemic non-cystic fibrosis cases from two tertiary care hospitals in north India. Indian J Med Res 2010;131:829-32
   PubMedGoogle Scholar
• Gautam V, Singhal L, Ray P. Burkholderia cepacia complex: beyond pseudomonas and acinetobacter. Indian J Med Microbiol 2011;29(1):4-12
   PubMed Web of Science ®Google Scholar
• Desai M, Buhler T, Weller PH, Brown MRW. Increasing resistance of planktonic and biofilm cultures of Burkholderia cepacia to ciprofloxacin and ceftazidime during exponential growth. J Antimicrob Chemother 1998;42(2):153-60
   PubMed Web of Science ®Google Scholar
• Tre-Hardy M, Mace C, El Manssouri N, et al. Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model. Int J Antimicrob Agents 2009;33(1):40-5
   PubMedGoogle Scholar
• Caraher E, Reynolds G, Murphy P, et al. Comparison of antibiotic susceptibility of Burkholderia cepacia complex organisms when grown planktonically or as biofilm in vitro. Eur J Clin Microbiol Infect Dis 2007;26(3):213-16
   PubMed Web of Science ®Google Scholar
• Peeters E, Nelis HJ, Coenye T, et al. In vitro activity of ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin and trimethoprim/sulfamethoxazole against planktonic and sessile Burkholderia cepacia complex bacteria. J Antimicrob Chemother 2009;64(4):801-9
   PubMed Web of Science ®Google Scholar
• Shaginian IA, Danilina GA, Chernukha M, et al. [Biofilm formation by strains of Burkholderia cepacia complex in dependence of their phenotypic and genotypic characteristics]. Zh Mikrobiol Epidemiol Immunobiol 2007(1):3-9
   PubMedGoogle Scholar
• Van Acker H, Sass A, Bazzini S, et al. Biofilm-grown Burkholderia cepacia complex cells survive antibiotic treatment by avoiding production of reactive oxygen species. PLoS One 2013;8(3):e58943
   PubMed Web of Science ®Google Scholar
• Messiaen AS, Forier K, Nelis H, et al. Transport of nanoparticles and tobramycin-loaded liposomes in Burkholderia cepacia complex biofilms. PLoS One 2013;8(11):e79220
   PubMed Web of Science ®Google Scholar
• Zlosnik JE, Hird TJ, Fraenkel MC, et al. Differential mucoid exopolysaccharide production by members of the Burkholderia cepacia complex. J Clin Microbiol 2008;46(4):1470-3
   PubMed Web of Science ®Google Scholar
• Bartholdson SJ, Brown AR, Mewburn BR, et al. Plant host and sugar alcohol induced exopolysaccharide biosynthesis in the Burkholderia cepacia complex. Microbiology 2008;154(Pt 8):2513-21
   PubMedGoogle Scholar
• Ferreira AS, Leitao JH, Sousa SA, et al. Functional analysis of Burkholderia cepacia genes bceD and bceF, encoding a phosphotyrosine phosphatase and a tyrosine autokinase, respectively: role in exopolysaccharide biosynthesis and biofilm formation. Appl Environ Microbiol 2007;73(2):524-34
   PubMedGoogle Scholar
• Chung JW, Speert DP. Proteomic identification and characterization of bacterial factors associated with Burkholderia cenocepacia survival in a murine host. Microbiology 2007;153(Pt 1):206-14
   PubMedGoogle Scholar
• Conway BA, Chu KK, Bylund J, et al. Production of exopolysaccharide by Burkholderia cenocepacia results in altered cell-surface interactions and altered bacterial clearance in mice. J Infect Dis 2004;190(5):957-66
   PubMedGoogle Scholar
• Zlosnik JE, Costa PS, Brant R, et al. Mucoid and nonmucoid Burkholderia cepacia complex bacteria in cystic fibrosis infections. Am J Respir Crit Care Med 2011;183(1):67-72
   PubMedGoogle Scholar
• Schwab U, Abdullah LH, Perlmutt OS, et al. Localization of Burkholderia cepacia complex bacteria in cystic fibrosis lungs and interactions with Pseudomonas aeruginosa in hypoxic mucus. Infect Immun 2014;82(11):4729-45
   PubMed Web of Science ®Google Scholar
• Nam SW, Chen X, Lim J, et al. In vivo fluorescence imaging of bacteriogenic cyanide in the lungs of live mice infected with cystic fibrosis pathogens. PLoS One 2011;6(7):e21387
   Google Scholar
• Brackman G, Cos P, Maes L, et al. Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo. Antimicrob Agents Chemother 2011;55(6):2655-61
   PubMed Web of Science ®Google Scholar
• Chu KK, Davidson DJ, Halsey TK, et al. Differential persistence among genomovars of the Burkholderia cepacia complex in a murine model of pulmonary infection. Infect Immun 2002;70(5):2715-20
   PubMedGoogle Scholar
• Kuti JL, Moss KM, Nicolau DP, Knauft RF. Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy. Pharmacotherapy 2004;24(11):1641-5
   PubMedGoogle Scholar
• Whitson BA, Hayes DJr. Indications and outcomes in adult lung transplantation. J Thorac Dis 2014;6(8):1018-23
   PubMedGoogle Scholar
• Boussaud V, Guillemain R, Grenet D, et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax 2008;63(8):732-7
   PubMed Web of Science ®Google Scholar
• Alexander BD, Petzold EW, Reller LB, et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplantat 2008;8(5):1025-30
   PubMed Web of Science ®Google Scholar
• De Soyza A, Meachery G, Hester KL, et al. Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience. J Heart Lung Transplant 2010;29(12):1395-404
   PubMed Web of Science ®Google Scholar
• Murray S, Charbeneau J, Marshall BC, LiPuma JJ. Impact of burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med 2008;178(4):363-71
   PubMed Web of Science ®Google Scholar
• Aris RM, Gilligan PH, Neuringer IP, et al. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med 1997;155(5):1699-704
   PubMed Web of Science ®Google Scholar
• Hoffman LR, Ramsey BW. Cystic fibrosis therapeutics: the road ahead. Chest 2013;143(1):207-13
   PubMed Web of Science ®Google Scholar
• Levasseur P, Girard AM, Claudon M, et al. In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2012;56(3):1606-8
   PubMed Web of Science ®Google Scholar
• Soubirou J. Temocillin an alternative to carbapenems for treat infections resistant enterobacteria to C3G? Journal Anti-infectieux 2013;15:60-7
   Google Scholar
• Balakrishnan I, Awad-El-Kariem FM, Aali A, et al. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2011;66(11):2628-31
   PubMed Web of Science ®Google Scholar
• Kent L, Bradley JM, France M, et al. Temocillin in cystic fibrosis: a retrospective pilot study. J Cyst Fibros 2008;7(6):551-4
   PubMedGoogle Scholar
• Kerr JR. In vitro activities of two drug combinations of ceftazidime, cefotaxime, cefuroxime, ciprofloxacin, chloramphenicol, imipenem and temocillin against clinical isolates of Pseudomonas cepacia from patients with cystic fibrosis. Int J Antimicrob Agents 1993;3(3):205-9
   PubMedGoogle Scholar
• Taylor RF, Gaya H, Hodson ME. Temocillin and cystic fibrosis: outcome of intravenous administration in patients infected with Pseudomonas cepacia. J Antimicrob Chemother 1992;29(3):341-4
   PubMedGoogle Scholar
• Chen Y, Garber E, Zhao Q, et al. In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2005;49(6):2510-11
   PubMedGoogle Scholar
• Singhal L, Gautam V, Kaur M, Ray P. In vitro activity of doripenem against Burkholderia cepacia complex isolates from non-cystic fibrosis patients. Antimicrob Agents Chemother 2011;55(3):1320-1
   PubMedGoogle Scholar
• Aronoff SC. Outer membrane permeability in Pseudomonas cepacia: diminished porin content in a beta-lactam-resistant mutant and in resistant cystic fibrosis isolates. Antimicrob Agents Chemother 1988;32(11):1636-9
   PubMedGoogle Scholar
• Parr TRJr, Moore RA, Moore LV, Hancock RE. Role of porins in intrinsic antibiotic resistance of Pseudomonas cepacia. Antimicrob Agents Chemother 1987;31(1):121-3
   PubMedGoogle Scholar
• Rajyaguru JM, Muszynski MJ. Enhancement of Burkholderia cepacia antimicrobial susceptibility by cationic compounds. J Antimicrob Chemother 1997;40(3):345-51
   PubMedGoogle Scholar
• Raetz CR, Reynolds CM, Trent MS, Bishop RE. Lipid A modification systems in gram-negative bacteria. Annu Rev Biochem 2007;76:295-329
   PubMed Web of Science ®Google Scholar
• Raetz CR, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem 2002;71:635-700
   PubMed Web of Science ®Google Scholar
• Shimomura H, Matsuura M, Saito S, et al. Unusual interaction of a lipopolysaccharide isolated from Burkholderia cepacia with polymyxin B. Infect Immun 2003;71(9):5225-30
   PubMedGoogle Scholar
• De Soyza A, Silipo A, Lanzetta R, et al. Chemical and biological features of Burkholderia cepacia complex lipopolysaccharides. Innate Immun 2008;14(3):127-44
   PubMedGoogle Scholar
• Bodewits K, Raetz CR, Govan JR, Campopiano DJ. Antimicrobial activity of CHIR-090, an inhibitor of lipopolysaccharide biosynthesis, against the Burkholderia cepacia complex. Antimicrob Agents Chemother 2010;54(8):3531-3
   PubMedGoogle Scholar
• Malott RJ, Steen-Kinnaird BR, Lee TD, Speert DP. Identification of hopanoid biosynthesis genes involved in polymyxin resistance in Burkholderia multivorans. Antimicrob Agents Chemother 2012;56(1):464-71
   PubMedGoogle Scholar
• Malott RJ, Wu CH, Lee TD, et al. Fosmidomycin decreases membrane hopanoids and potentiates the effects of colistin on Burkholderia multivorans clinical isolates. Antimicrob Agents Chemother 2014;58(9):5211-19
   PubMed Web of Science ®Google Scholar
• Aronoff SC. Derepressed beta-lactamase production as a mediator of high-level beta-lactam resistance in Pseudomonas cepacia. Pediatr Pulmonol 1988;4(2):72-7
   PubMedGoogle Scholar
• Hirai K, Iyobe S, Inoue M, Mitsuhashi S. Purification and properties of a new beta-lactamase from Pseudomonas cepacia. Antimicrob Agents Chemother 1980;17(3):355-8
   PubMedGoogle Scholar
• Chatterjee SS, Karmacharya R, Madhup SK, et al. High prevalence of co-expression of newer beta-lactamases (ESBLs, Amp-C-beta-lactamases, and metallo-beta-lactamases) in gram-negative bacilli. Indian J Med Microbiol 2010;28(3):267-8
   PubMedGoogle Scholar
• Trepanier S, Prince A, Huletsky A. Characterization of the penA and penR genes of Burkholderia cepacia 249 which encode the chromosomal class A penicillinase and its LysR-type transcriptional regulator. Antimicrob Agents Chemother 1997;41(11):2399-405
   PubMed Web of Science ®Google Scholar
• Papp-Wallace KM, Taracila MA, Gatta JA, et al. Insights into beta-lactamases from Burkholderia species, two phylogenetically related yet distinct resistance determinants. J Biol Chem 2013;288(26):19090-102
   PubMed Web of Science ®Google Scholar
• Ramirez MS, Vargas LJ, Cagnoni V, et al. Class 2 integron with a novel cassette array in a Burkholderia cenocepacia isolate. Antimicrob Agents Chemother 2005;49(10):4418-20
   PubMedGoogle Scholar
• Hancock RE. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis 1998;27(Suppl 1):S93-9
   PubMed Web of Science ®Google Scholar
• Burns JL, Wadsworth CD, Barry JJ, Goodall CP. Nucleotide sequence analysis of a gene from Burkholderia (Pseudomonas) cepacia encoding an outer membrane lipoprotein involved in multiple antibiotic resistance. Antimicrob Agents Chemother 1996;40(2):307-13
   PubMedGoogle Scholar
• Burns JL, Hedin LA, Lien DM. Chloramphenicol resistance in pseudomonas cepacia because of decreased permeability. Antimicrob Agents Chemother 1989;33(2):136-41
   PubMedGoogle Scholar
• Nair BM, Cheung KJJr, Griffith A, Burns JL. Salicylate induces an antibiotic efflux pump in Burkholderia cepacia complex genomovar III (B. cenocepacia). J Clin Invest 2004;113(3):464-73
   PubMedGoogle Scholar
• Nair BM, Joachimiak LA, Chattopadhyay S, et al. Conservation of a novel protein associated with an antibiotic efflux operon in Burkholderia cenocepacia. FEMS Microbiol Lett 2005;245(2):337-44
   PubMedGoogle Scholar
• Kohler T, Michea-Hamzehpour M, Henze U, et al. Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol 1997;23(2):345-54
   PubMed Web of Science ®Google Scholar
• Wigfield SM, Rigg GP, Kavari M, et al. Identification of an immunodominant drug efflux pump in Burkholderia cepacia. J Antimicrob Chemother 2002;49(4):619-24
   PubMedGoogle Scholar
• Guglierame P, Pasca MR, De Rossi E, et al. Efflux pump genes of the resistance-nodulation-division family in Burkholderia cenocepacia genome. BMC Microbiol 2006;6:66
   PubMed Web of Science ®Google Scholar
• Burns JL, Clark DK. Salicylate-inducible antibiotic resistance in Pseudomonas cepacia associated with absence of a pore-forming outer membrane protein. Antimicrob Agents Chemother 1992;36(10):2280-5
   PubMed Web of Science ®Google Scholar
• Buroni S, Pasca MR, Flannagan RS, et al. Assessment of three Resistance-Nodulation-Cell Division drug efflux transporters of Burkholderia cenocepacia in intrinsic antibiotic resistance. BMC Microbiol 2009;9:200
   PubMed Web of Science ®Google Scholar
• Rajendran R, Quinn RF, Murray C, et al. Efflux pumps may play a role in tigecycline resistance in Burkholderia species. Int J Antimicrob Agents 2010;36(2):151-4
   PubMed Web of Science ®Google Scholar
• Chiron R, Marchandin H, Counil F, et al. Clinical and microbiological features of Inquilinus sp. isolates from five patients with cystic fibrosis. J Clin Microbiol 2005;43(8):3938-43
   PubMedGoogle Scholar
• Coenye T, Goris J, Spilker T, et al. Characterization of unusual bacteria isolated from respiratory secretions of cystic fibrosis patients and description of Inquilinus limosus gen. nov., sp. nov. J Clin Microbiol 2002;40(6):2062-9
   PubMedGoogle Scholar
• Govan JR. Multidrug-resistant pulmonary infection in cystic fibrosis – what does ‘resistant’ mean? J Med Microbiol 2006;55(Pt 12):1615-17
   PubMedGoogle Scholar
• Nash EF, Coonar A, Kremer R, et al. Survival of Burkholderia cepacia sepsis following lung transplantation in recipients with cystic fibrosis. Transpl Infect Dis 2010;12(6):551-4
   PubMed Web of Science ®Google Scholar
• Fuchs PC, Barry AL, Thornsberry C, Jones RN. Interpretive criteria for temocillin disk diffusion susceptibility testing. Eur J Clin Microbiol 1985;4(1):30-3
   PubMedGoogle Scholar
• Van Acker H, Van Snick E, Nelis HJ, Coenye T. In vitro activity of temocillin against planktonic and sessile Burkholderia cepacia complex bacteria. J Cyst Fibros 2010;9(6):450-4
   PubMed Web of Science ®Google Scholar
• Bazzini S, Udine C, Sass A, et al. Deciphering the role of RND efflux transporters in Burkholderia cenocepacia. PLoS One 2011;6(4):e18902
   Google Scholar
• Rushton L, Sass A, Baldwin A, et al. A key role for efflux in the preservative susceptibility and adaptive resistance of Burkholderia cepacia complex bacteria. Antimicrob Agents Chemother 2013;57(7):2972-80
   PubMedGoogle Scholar
• Tseng SP, Tsai WC, Liang CY, et al. The Contribution of Antibiotic Resistance Mechanisms in Clinical Burkholderia cepacia Complex Isolates: an Emphasis on Efflux Pump Activity. PLoS One 2014;9(8):e104986
   PubMed Web of Science ®Google Scholar